Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | CCNK | O75909 | 2/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.40 |
| ▸ | EPHB3 | P54753 | 4/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15181320 | 0.83 | DYRK1A (0.51) | DYRK1ACCNKCDK12EPHB3RIPK2 | |
| SCHEMBL2346247 | 0.80 | EPHB3 (0.36) | DYRK1AEPHB3CDK2KDM4ECYP11B2 | |
| SCHEMBL376555 | 0.77 | CYP11B2 (0.36) | DRD2CYP11B2 | |
| SCHEMBL14663430 | 0.76 | DYRK1A (0.68) | DYRK1ACCNKCDK12EPHB3CDK2 | |
| SCHEMBL18302112 | 0.75 | DYRK1A (0.49) | DYRK1ACCNKCDK12EPHB3RIPK2 | |
| SCHEMBL376785 | 0.75 | JAK1 (0.48) | CDK2KDM4ENPC1HTTRAB9A | |
| SCHEMBL16739992 | 0.72 | PDE4B (0.43) | CDK2CYP11B2EGFR | |
| SCHEMBL3317508 | 0.72 | CDK2 (0.54) | DYRK1ACCNKCDK12CDK2CCNT1 | |
| SCHEMBL2346355 | 0.72 | DYRK1A (0.52) | DYRK1ACCNKCDK12EPHB3RIPK2 | |
| SCHEMBL3467001 | 0.71 | DYRK1A (0.55) | DYRK1ACCNKCDK12EPHB3ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | DYRK1A 2094/4885CCNK 686/4885CDK12 588/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | DYRK1A 1255/4885CCNK 55/4885CDK12 363/4885 |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | DYRK1A 1212/4885CCNK 380/4885CDK12 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.